Showing results (51-60 of 325) with videos related to

Sort By:
Pageof 33
Seminars in Thrombosis and Hemostasis|January 1, 1993
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin)W Jeske, B Lojewski, J M Walenga, et al.
Advances in Experimental Medicine and Biology|January 1, 1983
Inhibition of bradykinin-induced contraction of isolated smooth muscle tissue preparations by oligopeptide thiobenzyl ester substrates for serine proteasesJ Fareed, G Kindel, J M Walenga, et al.
Clinical Chemistry|September 1, 1983
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disordersJ Fareed, R L Bick, G Squillaci, et al.
Thrombosis Research|August 15, 1993
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal modelsP Bacher, J M Walenga, O Iqbal, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1986
Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transitionJ Fareed, J M Walenga, W H Baker, et al.
Thrombosis Research|July 1, 1988
The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activityJ M Walenga, L Bara, M Petitou, et al.
Advances in Experimental Medicine and Biology|January 1, 1995
Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disordersJ Fareed, D Hoppensteadt, L Iyer, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin)J Fareed, J M Walenga, D Hoppensteadt, et al.
Thrombosis Research|January 15, 1992
Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systemsB Kaiser, J Fareed, D Hoppensteadt, et al.
Thrombosis Research|May 15, 1993
A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate modelP Bacher, O Iqbal, B Lojewski, et al.
Pageof 33